The role of losartan in cost-effective hypertension control

Current Medical Research and Opinion

Volumn 18, Issue 3, 2002, Pages 139-145

  McIntyre, Huge ^a   Costa, F V ^a   Dusing R ^a   Ambrosioni, E ^a   Gerth, W ^a  

^a East Sussex Healthcare NHS Trust   (United Kingdom)

Author keywords

Angiotensin II antagonists; Antihypertensives; Compliance; Cost effectiveness; Hypertension; Losartan

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LOSARTAN; METOPROLOL; VALSARTAN;

ARTICLE; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; HEALTH CARE COST; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; SIDE EFFECT; COST BENEFIT ANALYSIS; ECONOMICS; GERMANY; ITALY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; GERMANY; GREAT BRITAIN; HUMAN; HYPERTENSION; ITALY; LOSARTAN; PATIENT COMPLIANCE; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; HUMANS;

EID: 0035991604     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000499     Document Type: Article

References (49)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
2. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
3. Control of blood pressure in Scotland: The rule of halves
4. Prevalence, treatment, control, and awareness of high blood pressure and the risk of stroke in Northwest England
5. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991
6. Detection and control of high blood pressure in the community: Do we need a wake-up call?
7. Long-term cost and life-expectancy consequences of hypertension
8. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension
9. Cognitive decline in individuals with high blood pressure: A longitudinal study in the elderly. EVA Study Group. Epidemiology of vascular aging
10. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension
11. Compliance with antihypertensive therapy: Raising the bar of expectations
12. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
13. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
14. Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension
15. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
16. Cardioprotective effect of angiotensin II receptor antagonists
17. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991
18. Public awareness of hypertension declines in US
19. Factors associated with noncompliance of patients taking antihypertensive medications
20. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence
21. Costs associated with noncompliance
22. Adherence to antihypertensive medications across the life span
23. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly
24. A survey of the current practice of treating hypertension in primary care: The Rational Evaluation and Choice in Hypertension (REACH) study
25. Variations in compliance among hypertensive patients by drug class: Implications for health care costs
26. The health economics of the treatment of hyperlipidemia and hypertension
27. The cost effectiveness of hypertension treatment in Sweden
28. The cost of hypertension and its correlates in Emilia Romagna region (Italy): Results from the GREAT study
29. The effect of drug cost on hypertension treatment decision
30. Medical and cost-economy aspects of modern antihypertensive therapy with special reference to 2 years of clinical experience with losartan
31. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension
32. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: A comparison of older and newer agents
33. Costs associated with changing antihypertensive drug monotherapy: 'Preferred' vs. 'alternative' therapy
34. Continuation of initial antihypertensive medication after 1 year of therapy
35. Compliance with antihypertensive therapy. Comparison of losartan, amlodipine, and metoprolol in an open prospective trial
36. Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: A community based study of a losartan-based regimen vs. usual care
37. Mangement of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: Case histories
38. The choice of antihypertensive drugs in patients with erectile dysfunction
39. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
40. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - A randomized controlled trial
41. Losartan: A study of pharmacovigilance data on 14,522 patients
42. Patients' experiences of antihypertensive drugs in routine use: Results of a Danish general practice survey
43. Costs of mini mental state examination-related cognitive impairment
44. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients
45. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
46. Excerpts from the United States Renal Data System's 2000 annual data report: Atlas of end-stage renal disease in the United States: Economic costs of ESRD
47. Healthcare systems and end-stage renal disease (ESRD) therapies - An international review: Costs and reimbursement/funding of ESRD therapies
48. Cost-benefit analysis of angiotensin II receptor antagonists in antihypertensive therapy
49. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials